Lexicon Pharmaceuticals, Inc. (LXRX) has a negative trailing P/E of -12.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 175.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -7.98%, forward earnings yield 0.57%. PEG 0.35 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 47/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -10.2 | 0.00 | 9.13 | 17.24 | - |
| 2017 | -8.0 | 0.84 | 19.93 | 11.50 | - |
| 2018 | -5.8 | 0.80 | -0.48 | 11.11 | - |
| 2019 | 3.4 | -0.02 | 3.76 | 1.37 | - |
| 2020 | -6.5 | 0.04 | 2.42 | 15.80 | - |
| 2021 | -6.5 | 2.06 | 5.05 | 1,925.73 | - |
| 2022 | -3.1 | -1.89 | 2.70 | 2,277.34 | - |
| 2023 | -1.9 | -0.07 | 3.63 | 281.00 | - |
| 2024 | -1.2 | 0.06 | 1.62 | 7.60 | - |
| 2025 | -8.3 | 0.11 | 3.88 | 8.38 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.36 | $83.34M | $-141.43M | -169.7% |
| 2017 | $-1.23 | $90.34M | $-129.05M | -142.9% |
| 2018 | $-1.14 | $63.21M | $-120.55M | -190.7% |
| 2019 | $1.11 | $322.07M | $130.13M | 40.4% |
| 2020 | $-0.63 | $24M | $-70.18M | -292.5% |
| 2021 | $-0.61 | $298K | $-88.27M | -29620.1% |
| 2022 | $-0.62 | $139K | $-103.13M | -74192.8% |
| 2023 | $-0.80 | $1.2M | $-177.12M | -14710.9% |
| 2024 | $-0.63 | $31.08M | $-200.4M | -644.8% |
| 2025 | $-0.14 | $49.8M | $-50.34M | -101.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.18 | $-0.19 – $-0.17 | $33.92M | $31.09M – $35.97M | 4 |
| 2027 | $-0.21 | $-0.27 – $-0.14 | $19.63M | $13.66M – $25.61M | 4 |
| 2028 | $-0.11 | $-0.18 – $0.02 | $68.76M | $56.4M – $79.47M | 4 |
| 2029 | $0.01 | $0.01 – $0.01 | $125.46M | $102.91M – $145.01M | 2 |
| 2030 | $0.06 | $0.05 – $0.07 | $157.63M | $129.3M – $182.21M | 2 |
